INAB
IN8bio, Inc.
Biotechnology
Market Cap$6M
5Y Perf.-99.5%
Build Your Comparison
Side-by-side financial analysisINAB
FATE
Try popular comparisons:
Stock Comparison
INAB vs FATE
Revenue, margins, valuation, and 5-year total return — side by side.
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$221M
5Y Perf.-97.7%
INAB vs FATE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  INAB |  FATE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $6M | $221M |
| Revenue (TTM) | $0.00 | $6M |
| Net Income (TTM) | $-19M | $-130M |
| Gross Margin | — | 53.8% |
| Operating Margin | — | -22.1% |
| Total Debt | $3M | $78M |
| Cash & Equiv. | $27M | $47M |
INAB vs FATE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
INAB
FATE
| Stock | Jul 21 | Jun 26 | Return |
|---|---|---|---|
| IN8bio, Inc. (INAB) | 100 | 0.5 | -99.5% |
| Fate Therapeutics, … (FATE) | 100 | 2.3 | -97.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INAB vs FATE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: INAB leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Fate Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇INAB emerged as the overall leader. Track its performance:
INAB
IN8bio, Inc.
The Income Pick
INAB carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.89
- Lower volatility, beta 1.89, Low D/E 10.1%, current ratio 8.82x
- Beta 1.89, current ratio 8.82x
Best for: income & stability and sleep-well-at-night
FATE
Fate Therapeutics, Inc.
The Growth Play
FATE is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -51.2%, EPS growth 29.9%, 3Y rev CAGR -59.0%
- 8.0% 10Y total return vs INAB's -99.5%
- +53.2% vs INAB's -37.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  INAB | 32.1% revenue growth vs FATE's -51.2% |
| Quality / Margins | INAB | 1.3% margin vs FATE's -20.6% |
| Stability / Safety | INAB | Beta 1.89 vs FATE's 1.93, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) |  FATE | +53.2% vs INAB's -37.6% |
| Efficiency (ROA) | FATE | -39.4% ROA vs INAB's -80.2%, ROIC -36.5% vs -256.0% |
INAB vs FATE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
INAB vs FATE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFATELAGGINGINAB
INABIN8bio, Inc.
0leads
FATEFate Therapeutics, In…
2leads
6 Total Categories
CATEGORYLEADERvs INABMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FATE1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
FATE6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FATE leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
FATE and INAB operate at a comparable scale, with $6M and $0 in trailing revenue.
| Metric | INABIN8bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $6M |
| EBITDAEarnings before interest/tax | -$17M | -$127M |
| Net IncomeAfter-tax profit | -$19M | -$130M |
| Free Cash FlowCash after capex | -$15M | -$108M |
| Gross MarginGross profit ÷ Revenue | — | +53.8% |
| Operating MarginEBIT ÷ Revenue | — | -22.1% |
| Net MarginNet income ÷ Revenue | — | -20.6% |
| FCF MarginFCF ÷ Revenue | — | -17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -20.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.9% | +18.8% |
FATE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — INAB and FATE each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | INABIN8bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| Market CapShares × price | $6M | $221M |
| Enterprise ValueMkt cap + debt − cash | -$18M | $253M |
| Trailing P/EPrice ÷ TTM EPS | -0.31x | -1.65x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 33.32x |
| Price / BookPrice ÷ Book value/share | 0.22x | 1.09x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — INAB and FATE each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — INAB and FATE each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
FATE delivers a -58.9% return on equity — every $100 of shareholder capital generates $-59 in annual profit, vs $-96 for INAB. INAB carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to FATE's 0.38x. On the Piotroski fundamental quality scale (0–9), INAB scores 5/9 vs FATE's 2/9, reflecting solid financial health.
| Metric | INABIN8bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | -96.4% | -58.9% |
| ROA (TTM)Return on assets | -80.2% | -39.4% |
| ROICReturn on invested capital | -2.6% | -36.5% |
| ROCEReturn on capital employed | -84.5% | -43.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 |
| Debt / EquityFinancial leverage | 0.10x | 0.38x |
| Net DebtTotal debt minus cash | -$24M | $31M |
| Cash & Equiv.Liquid assets | $27M | $47M |
| Total DebtShort + long-term debt | $3M | $78M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Evenly matched — INAB and FATE each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
FATE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FATE five years ago would be worth $230 today (with dividends reinvested), compared to $46 for INAB. Over the past 12 months, FATE leads with a +53.2% total return vs INAB's -37.6%. The 3-year compound annual growth rate (CAGR) favors FATE at -30.2% vs INAB's -71.3% — a key indicator of consistent wealth creation.
| Metric | INABIN8bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | -43.9% | +91.9% |
| 1-Year ReturnPast 12 months | -37.6% | +53.2% |
| 3-Year ReturnCumulative with dividends | -97.6% | -65.9% |
| 5-Year ReturnCumulative with dividends | -99.5% | -97.7% |
| 10-Year ReturnCumulative with dividends | -99.5% | +8.0% |
| CAGR (3Y)Annualised 3-year return | -71.3% | -30.2% |
FATE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — INAB and FATE each lead in 1 of 2 comparable metrics.
Risk & Volatility
INAB is the less volatile stock with a 1.89 beta — it tends to amplify market swings less than FATE's 1.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FATE currently trades 66.0% from its 52-week high vs INAB's 50.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INABIN8bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.89x | 1.93x |
| 52-Week HighHighest price in past year | $2.73 | $2.88 |
| 52-Week LowLowest price in past year | $1.17 | $0.91 |
| % of 52W HighCurrent price vs 52-week peak | +50.5% | +66.0% |
| RSI (14)Momentum oscillator 0–100 | 38.9 | 48.9 |
| Avg Volume (50D)Average daily shares traded | 62K | 3.2M |
Evenly matched — INAB and FATE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | INABIN8bio, Inc. | FATEFate Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $5.50 |
| # AnalystsCovering analysts | — | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FATE leads in 2 of 6 categories — strongest in Income & Cash Flow and Total Returns. 3 categories are tied.
Best OverallFate Therapeutics, Inc. (FATE)Leads 2 of 6 categories
Loading custom metrics...
INAB vs FATE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is INAB or FATE a better buy right now?
Analysts rate Fate Therapeutics, Inc.
(FATE) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INAB or FATE?
Over the past 5 years, Fate Therapeutics, Inc.
(FATE) delivered a total return of -97. 7%, compared to -99. 5% for IN8bio, Inc. (INAB). Over 10 years, the gap is even starker: FATE returned +8. 0% versus INAB's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INAB or FATE?
By beta (market sensitivity over 5 years), IN8bio, Inc.
(INAB) is the lower-risk stock at 1. 89β versus Fate Therapeutics, Inc. 's 1. 93β — meaning FATE is approximately 2% more volatile than INAB relative to the S&P 500. On balance sheet safety, IN8bio, Inc. (INAB) carries a lower debt/equity ratio of 10% versus 38% for Fate Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — INAB or FATE?
On earnings-per-share growth, the picture is similar: Fate Therapeutics, Inc.
grew EPS 29. 9% year-over-year, compared to -678. 9% for IN8bio, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — INAB or FATE?
IN8bio, Inc.
(INAB) is the more profitable company, earning 0. 0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INAB leads at 0. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — INAB leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — INAB or FATE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is INAB or FATE better for a retirement portfolio?
For long-horizon retirement investors, Fate Therapeutics, Inc.
(FATE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. IN8bio, Inc. (INAB) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FATE: +8. 0%, INAB: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between INAB and FATE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.